Edition:
India

Novelion Therapeutics Inc (NVLN.OQ)

NVLN.OQ on NASDAQ Stock Exchange Global Select Market

5.26USD
17 Nov 2017
Change (% chg)

$0.29 (+5.84%)
Prev Close
$4.97
Open
$4.99
Day's High
$5.36
Day's Low
$4.98
Volume
19,075
Avg. Vol
22,497
52-wk High
$12.09
52-wk Low
$4.21

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2017 Sep '17 28.67 -2.668
Jun '17 40.88 -1.152
Mar '17 29.98 -1.670
FY 2016 Dec '16 13.57 -1.482
Sep '16 0.00 -0.562
Jun '16 0.00 -0.485
Mar '16 0.00 -2.072
FY 2015 Dec '15 0.00 -0.348
Sep '15 0.00 -0.254
Jun '15 0.00 -1.038
Mar '15 0.00 -0.575
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Dec-17 2 32.80 34.00 31.60 0.00
Year Ending Dec-17 2 132.35 133.50 131.20 0.00
Year Ending Dec-18 2 155.00 161.10 148.90 78.50
Earnings (per share)
Quarter Ending Dec-17 2 -1.60 -0.30 -2.90 -0.40
Year Ending Dec-17 1 -7.44 -7.44 -7.44 -2.20
Year Ending Dec-18 2 -3.23 -1.14 -5.33 5.05
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

Dividends

Growth Rates

Financial Strength

Profitability Ratios

Efficiency

Management Effectiveness

  1 Year 3 Year 5 Year
Sales % -- -- --
EPS (TTM) % -112.47 -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for Novelion Therapeutics Inc

Period %
Actual
% vs.
S&P 500
Rank In
Industry
Industry
Rank
4 Week -0.42 -3.86 42 --
13 Week -24.41 -28.09 17 --
26 Week -33.93 -38.95 21 --
52 Week -31.41 -41.87 30 --
YTD -16.51 -26.68 31 --
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 77.68%
# of Holders: 101
Total Shares Held: 14,488,293
3 Mo. Net Change: -562,554
# New Positions: 7
# Closed Positions: 13
# Increased Positions: 28
# Reduced Positions: 41
# Net Buyers: -13
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.